PATH Share Price

Open 4.20 Change Price %
High 4.33 1 Day 0.07 1.67
Low 4.18 1 Week 0.00 0.00
Close 4.25 1 Month 0.00 0.00
Volume 657476 1 Year 0.00 0.00
52 Week High 4.44
52 Week Low 0.00
PATH Important Levels
Resistance 2 4.39
Resistance 1 4.33
Pivot 4.25
Support 1 4.17
Support 2 4.11
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
FTR 1.46 12.31%
FTR 1.46 12.31%
SUSQ 14.20 -0.77%
CSCO 31.21 -0.54%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.08 60.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CMLS 0.49 25.64%
OTT 2.39 25.13%
EVEP 1.30 18.18%
ARNA 1.33 15.65%
INVE 5.72 14.86%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

NuPathe Inc. (NASDAQ: PATH)

PATH Technical Analysis 5
As on 21st Feb 2014 PATH Share Price closed @ 4.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.95 & Strong Buy for SHORT-TERM with Stoploss of 3.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
PATH Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PATH Other Details
Segment EQ
Market Capital 52411492.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
PATH Address
PATH
N/A
PATH Latest News
Interactive Technical Analysis Chart NuPathe Inc. ( PATH NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on NuPathe Inc.
PATH Business Profile
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.